NCT01152853View on ClinicalTrials.gov

PF-00299804 Monotherapy in Patients With HER-2 Positive Advance Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

July 31, 2011

Study Completion Date

September 30, 2012

Conditions
Advanced Gastric CancerHER2
Interventions
DRUG

PF00299804

PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.

Trial Locations (1)

110-744

Seoul National University Hospital, Seoul

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Seoul National University Hospital

OTHER